Allogeneic Cell Therapy Global Market Report 2024

The allogenic cell therapy market size has grown rapidly in recent years. It will grow from $0.97 billion in 2023 to $1.08 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth observed in the historical period can be credited to a heightened emphasis on customizing donor cell selection and genetic modifications, an expanding population, a rise in the global burden of chronic diseases, heightened awareness, and an increase in collaborations for biosimilar development.

The allogenic cell therapy market size is expected to see rapid growth in the next few years. It will grow to $1.67 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast is driven by the escalating demand for advanced medical treatments, a burgeoning need for innovative allogeneic cell therapies, a surge in clinical trial activities, growing contributions from patient populations, and escalating income levels. Noteworthy trends anticipated during the forecast period include technological advancements, strategic partnerships, collaborations among major companies, mergers and acquisitions, and the introduction of new products.

The rise in chronic diseases is expected to propel the expansion of the allogeneic cell therapy market. Chronic illnesses, characterized by prolonged duration and necessitating continual medical care, can impede daily functioning and diminish life quality. These conditions' prevalence stems from altered lifestyle habits, genetic inheritance, and exposure to environmental toxins and pollutants. Allogeneic cell therapy offers substantial promise in addressing a broad spectrum of chronic diseases, utilizing healthy donor cells to repair, substitute, or regulate dysfunctional recipient cells or tissues. For example, a report from the National Center for Biotechnology Information (NCBI) projected a 99.5% increase in individuals aged 50 and above suffering from one or more chronic ailments by 2050, rising from 71.52 million in 2020 to 142.66 million. Consequently, the escalating occurrence of chronic diseases propels the allogeneic cell therapy market's growth.

Key players in the allogeneic cell therapy sector are concentrating on pioneering solutions, such as cell processing platforms, to fortify their market standing. These platforms encompass systems and technologies employed in preparing and manipulating cells for therapeutic purposes, including isolation, purification, expansion, modification, and quality assurance to ensure clinical suitability. For instance, in March 2024, Getinge, a Swedish healthcare entity, collaborated with CellRev, a UK biotech firm, to introduce Livit ACE, a continuous cell processing platform for Adherent Cell Expansion (ACE). This cutting-edge platform integrates advanced automation and bioprocessing technologies, markedly augmenting cell production efficiency and scalability. Notable features include top-tier cell isolation and purification systems ensuring high purity and viability, robust expansion capabilities for generating ample therapeutic cells, advanced genetic modification tools for precise cell engineering, and stringent quality control protocols to ensure product safety and efficacy.

In November 2021, Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical giant, acquired GammaDelta Therapeutics Limited for an undisclosed sum. This acquisition aims to bolster Takeda's cell therapy and immuno-oncology capabilities by leveraging GammaDelta Therapeutics' pioneering approach in harnessing gamma-delta (γδ) T cells. GammaDelta Therapeutics Limited, based in the UK, specializes in developing allogeneic gamma delta T cell therapies.

Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, TrakCel Ltd., Promab Biotechnologies Inc., Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Minerva Biotechnologies Corporation, Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG.

North America was the largest region in the allogeneic cell therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the allogeneic cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Allogeneic cell therapy involves harvesting cells from a donor to treat a recipient. Its purpose is to replace or repair damaged tissues, modulate immune responses, or address conditions such as cancer, genetic disorders, and autoimmune diseases.

There are two main types of allogeneic cell therapy stem cell therapies and non-stem cell therapies. Stem cell therapies use stem cells to repair or replace damaged tissues or organs, aiming to prevent or treat a range of diseases and conditions. These therapies are applied in various medical fields, including hematological disorders, dermatological disorders, and other therapeutic areas, utilized by hospitals, specialty clinics, and research organizations.

The allogenic cell therapy market research report is one of a series of new reports that provides allogenic cell therapy market statistics, including allogenic cell therapy industry global market size, regional shares, competitors with a allogenic cell therapy market share, detailed allogenic cell therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the allogenic cell therapy industry. This allogenic cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The allogeneic cell therapy market includes revenues earned by entities through induced pluripotent stem cell therapy, hematopoietic stem cell transplantation, mesenchymal stem cell (MSC) therapy, induced pluripotent stem cell (IPSC) therapy and chimeric antigen receptor T cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.